Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL9520159 | 1.00 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Piperidine SCHEMBL15517892 | 0.97 | ALDH1A1 (0.56) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Piperidine SCHEMBL15511100 | 0.97 | ALDH1A1 (0.56) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Piperidine SCHEMBL15511101 | 0.97 | ALDH1A1 (0.56) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Azepane SCHEMBL5164365 | 0.97 | ALDH1A1 (0.56) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Piperidine SCHEMBL15517893 | 0.97 | ALDH1A1 (0.56) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Pyrrolidine SCHEMBL11618713 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Piperidine SCHEMBL15570570 | 0.94 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Piperidine SCHEMBL15572305 | 0.94 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA | |
| Piperidine SCHEMBL28020374 | 0.94 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2CA2CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934694-B1 | ANTI-PLAQUE ORAL COMPOSITIONS | BHUSHAN RAJIV (US) | 2023-06-28 | — | — | EP | claimed |
| EP-3105310-B1 | NOVEL PERACID-CONTAINING PARTICLE | SOC CHIMICA BUSSI S P A (IT) | 2020-05-27 | — | — | EP | claimed |
| EP-1633471-B2 | PERCARBOXYLIC ACID-BASED POLYELECTROLYTE CAPSULE SYSTEM HAVING A LONG SHELF LIFE | HENKEL AG & CO KGAA (DE) | 2017-10-18 | — | — | EP | claimed |
| EP-3105310-A2 | NOVEL PERACID-CONTAINING PARTICLE | Revolymer (U.K.) Limited (GB) | 2016-12-21 | — | — | EP | claimed |
| US-20160348037-A1 | NOVEL PERACID-CONTAINING PARTICLE | REVOLYMER (U.K.) LIMITED (GB) | 2016-12-01 | — | — | US | claimed |
| EP-1633468-B2 | LIQUID WASHING OR CLEANING AGENT COMPOSITIONS COMPRISING PERCARBOXYLIC ACID-BASED CAPSULES HAVING A LONG SHELF LIFE | HENKEL AG & CO KGAA (DE) | 2016-10-19 | — | — | EP | claimed |
| EP-1948773-B1 | FRAGRANT CONSUMER PRODUCTS COMPRISING OXIDIZING AGENTS | HENKEL AG & CO KGAA (DE) | 2016-03-30 | — | — | EP | claimed |
| US-20150335557-A1 | ANTI-PLAQUE ORAL COMPOSITIONS | BHUSNAN RAJIV (US) | 2015-11-26 | — | — | US | claimed |
| EP-2934694-A1 | ANTI-PLAQUE ORAL COMPOSITIONS | Bhushan, Rajiv (US) | 2015-10-28 | — | — | EP | claimed |
| WO-2015118357-A2 | NOVEL PERACID-CONTAINING PARTICLE | REVOLYMER (U.K) LIMITED (GB) | 2015-08-13 | — | — | WO | claimed |
| EP-1633470-B1 | PERCARBOXYLIC ACID-BASED BLEACH COMPOSITIONS HAVING A LONG SHELF LIFE | HENKEL AG & CO KGAA (DE) | 2010-07-21 | — | — | EP | claimed |
| EP-1633469-B1 | METHOD FOR STABILISING PEROXYCARBOXYLIC ACIDS IN DISPERSIONS CONTAINING SURFACTANTS | HENKEL AG & CO KGAA (DE) | 2009-11-25 | — | — | EP | claimed |
| EP-1633471-B1 | PERCARBOXYLIC ACID-BASED POLYELECTROLYTE CAPSULE SYSTEM HAVING A LONG SHELF LIFE | HENKEL AG & CO KGAA (DE) | 2009-03-25 | — | — | EP | claimed |
| EP-1633468-B1 | PERCARBOXYLIC ACID-BASED CAPSULES HAVING A LONG SHELF LIFE | HENKEL AG & CO KGAA (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20070032396-A1 | Peroxycarboxylic acid-based capsules having a long shelf life | HENKEL AG & CO. KGAA (DE) | 2007-02-08 | — | — | US | claimed |
| US-20060178284-A1 | Method for stabilizing percarboxylic acids in dispersions containing surfactants | HENKEL AG & CO. KGAA (DE) | 2006-08-10 | — | — | US | claimed |
| US-20060178285-A1 | Peroxycaboxylic acid-based bleach compositions having a long shelf life | HENKEL AG & CO. KGAA (DE) | 2006-08-10 | — | — | US | claimed |
| US-20060172909-A1 | Peroxycarboxylic acid-based polyelectrolyte capsule system having a long shelf life | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2006-08-03 | — | — | US | claimed |
| US-5158763-A | Azacycloalkane diphosphonic acid or salt | COLGATE-PALMOLIVE COMPANY (US) | 1992-10-27 | — | — | US | claimed |
| EP-0480811-A2 | Non-staining anti-bacterial oral composition | Colgate-Palmolive Company (a Delaware corporation) (US) | 1992-04-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335557-A1 | ANTI-PLAQUE ORAL COMPOSITIONS | MGMT, CAPG, TRPM7 | ALDH1A1 4865/4885CXCR4 3263/4885SMN1; SMN2 2331/4885 |
| US-20160348037-A1 | NOVEL PERACID-CONTAINING PARTICLE | POLR1C, SDC1, PBDC1 | ALDH1A1 2263/4885CXCR4 4688/4885SMN1; SMN2 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.